Literature DB >> 8149962

Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG.

U Skansén-Saphir1, J Andersson, L Björk, U Andersson.   

Abstract

The influence of pooled human IgG preparations for intravenous use (IVIg) on cytokine production induced by streptococcal pyrogenic exotoxin-A (SPE-A) was studied at the single-cell level using cytokine-specific monoclonal antibodies and indirect immunofluorescence or immunohistochemical staining. Mononuclear cells from healthy adult blood donors were stimulated with SPE-A alone or in the presence of IVIg. IVIg was added either prior to stimulation or 24 h after initiation of cultures, in an attempt to evaluate whether IVIg treatment could influence an already established systemic streptococcal disease. Cells were harvested after 48 or 72 h of culture and stained for the following cytokines: interleukin(IL)-1 alpha, IL-1 beta, IL-1ra, IL-6, IL-8, IL-2, tumor necrosis factor interferon(IFN)-gamma and TNF-alpha and TNF-beta and granulocyte macrophage-colony-stimulating factor. Stimulation with SPE-A lead to extensive lymphokine and monokine production. With the addition of IVIg prior to stimulation there was a strong reduction of blast transformation and an almost complete inhibition of lymphokine production, in particular in the synthesis of IFN-gamma and TNF-beta while the synthesis of IL-1 and IL-8 was either unaffected or increased. Adding IVIg 24 h after SPE-A stimulation also resulted in reduced blast transformation and decreased synthesis of IFN-gamma and TNF-beta. These results indicate an immunomodulatory potential by IVIg on streptococcally induced T cell activation and lymphokine production.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8149962     DOI: 10.1002/eji.1830240420

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections.

Authors:  H Basma; A Norrby-Teglund; A McGeer; D E Low; O El-Ahmedy; J B Dale; B Schwartz; M Kotb
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 2.  Bacterial pyrogenic exotoxins as superantigens.

Authors:  M Kotb
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

3.  In vivo modulation of cytokine synthesis by intravenous immunoglobulin.

Authors:  W A Sewell; M E North; R Cambronero; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

4.  Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production.

Authors:  T Darville; L B Milligan; K K Laffoon
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

5.  Group A streptococcal toxic shock syndrome with severe necrotizing fasciitis following hysterectomy--a case report.

Authors:  M Loscar; G Schelling; M Haller; J Polasek; C Stoll; U Kreimeier; U Finsterer; H O Steitz; R Baumeister; R Kimmig; B Grabein; J Briegel
Journal:  Intensive Care Med       Date:  1998-02       Impact factor: 17.440

6.  Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G.

Authors:  A Norrby-Teglund; R Kaul; D E Low; A McGeer; J Andersson; U Andersson; M Kotb
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

7.  Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD).

Authors:  Y Takata; S Seki; H Dobashi; S Takeshita; K Nakatani; Y Kamezawa; H Hiraide; I Sekine; S Yoshioka
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  Streptococcus pyogenes evades adaptive immunity through specific IgG glycan hydrolysis.

Authors:  Andreas Naegeli; Eleni Bratanis; Christofer Karlsson; Oonagh Shannon; Raja Kalluru; Adam Linder; Johan Malmström; Mattias Collin
Journal:  J Exp Med       Date:  2019-05-15       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.